Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkins Lymphoma - WAFB 9 News Baton Rouge, Louisiana News, Weather, Sports

Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkins Lymphoma

Posted:

This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.

SOURCE:

Throughout this trial, Intrinsic Imaging will provide comprehensive imaging core lab services including, but not limited to, protocol and charter development, site qualification, site training and management, image transfer, blinding and processing as well as the specialized radiologic review of images acquired using positron emission tomography coupled with computed tomography (PET/CT), or PET coupled with magnetic resonance imaging (PET/MRI).

Boston, MA, San Antonio, TX (PRWEB) August 29, 2014

Intrinsic Imaging, an FDA audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant imaging core lab, announced today that it has been awarded an international Phase II clinical trial to assess a new treatment for patients with non-Hodgkins lymphoma.

Throughout this trial, Intrinsic Imaging will provide comprehensive imaging core lab services including, but not limited to, protocol and charter development, site qualification, site training and management, image transfer, blinding and processing as well as the specialized radiologic review of images acquired using positron emission tomography coupled with computed tomography (PET/CT), or PET coupled with magnetic resonance imaging (PET/MRI).

Intrinsic Imagings more than sixty board-certified radiologists have fellowship training in all subspecialty therapeutic areas including Oncology. The Oncology team consists of 12 full-time board-certified, fellowship trained radiologists all of whom have significant expertise in the evaluation of many cancers including but not limited to breast, cervical, colorectal, gastric, head and neck, lung, lymphoma, melanoma, ovarian, prostate, renal and thyroid.

At Intrinsic Imaging, we are able to provide our wealth of oncology expertise to the design and management of clinical trials and to the determination of drug efficacy and/or disease progression, said Todd A. Joron, BSc. MBA, President and Chief Operating Officer, Intrinsic Imaging. Of the more than 1 million images reviewed annually by Intrinsic Imaging radiologists, 400,000 images are oncology related.

Non-Hodgkin's lymphoma is cancer that originates in the lymphatic system. According to their April 2014 report, the Leukemia and Lymphoma Society estimate there are 558,340 people in the United States who are living with the disease or are in remission and another 70,800 new cases of non-Hodgkins lymphoma are expected to be diagnosed. Non-Hodgkin's lymphoma is the seventh most common cause of cancer related deaths in the United States.

About Intrinsic Imaging LLC
Located in Bolton, Massachusetts and San Antonio, Texas, Intrinsic Imaging is an FDA audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 medical imaging core lab specializing in providing imaging core lab services for clinical trials. With its team of more than sixty board-certified diagnostic radiologists, robust and scalable clinical imaging technologies and our ISO certified and registered quality management systems, Intrinsic Imaging is ideally positioned to provide unprecedented imaging core lab services around the world. For more information, please visit http://www.IntrinsicCRO.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/2014/08/prweb12127480.htm

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

Powered by WorldNow